


Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application.


Listing of Claims:

Claim 1 (previously presented): A process for the manufacture of the calcium salt of (*E*)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3*R*,5*S*)-3,5-dihydroxyhept-6-enoic acid, comprising:

- a) acid hydrolysis of an acetal protecting group in a compound of formula (7)




wherein A is an acetal or ketal protecting group and R is (1-6C)alkyl, and isolation of a resulting crystalline compound of formula (8)



- b) optional recrystallisation of the compound of formula (8);


c) hydrolysis of the ester group in the compound of formula (8) to give a dihydroxy carboxylate derivative of formula (9), wherein M is hydrogen or a metal counterion other than calcium,



or the calcium salt of (*E*)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3*R*,5*S*)-3,5-dihydroxyhept-6-enoic acid; and

d) conversion of the compound of formula (9), where present, into the calcium salt of (*E*)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3*R*,5*S*)-3,5-dihydroxyhept-6-enoic acid.

Claim 2 (previously presented): The process as claimed in Claim 1 wherein the compound of formula (7) is a compound of formula (7a).



Claim 3 (original): A process for the manufacture of the calcium salt of (*E*)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3*R*,5*S*)-3,5-dihydroxyhept-6-enoic acid, from a crystalline compound of formula (8) as claimed in steps c) and d) of Claim 1.

Claim 4 (previously presented): The process as claimed in Claim 1 wherein R is methyl, ethyl, iso-propyl, tert-butyl or hexyl.

Claim 5 (previously presented): The process as claimed in Claim 1 wherein R is ethyl, iso-propyl or tert-butyl.

Claim 6 (previously presented): A crystalline compound of the formula (7) as defined in Claim 1, which crystalline compound is methyl (*E*)-(6-{2-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]vinyl}(4*R*,6*S*)-2,2-dimethyl[1,3]dioxan-4-yl)acetate having an X-ray powder diffraction pattern with peaks at 2-theta = 9.5, 13.6 and 17.5.

Claim 7 (previously presented): A crystalline compound of the formula (7) as defined in Claim 1, which crystalline compound is ethyl (*E*)-(6-{2-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]vinyl}(4*R*,6*S*)-2,2-dimethyl[1,3]dioxan-4-yl)acetate having an X-ray powder diffraction pattern with peaks at 2-theta = 15.9, 18.4 and 19.5.

Claim 8 (previously presented): A crystalline compound of the formula (7) as defined in Claim 1, which crystalline compound is iso-propyl (*E*)-(6-{2-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]vinyl}(4*R*,6*S*)-2,2-dimethyl[1,3]dioxan-4-yl)acetate having an X-ray powder diffraction pattern with peaks at 2-theta = 7.8, 11.6 and 15.5.

Claim 9 (previously presented): A crystalline compound of the formula (7) as defined in Claim 1, which crystalline compound is n-hexyl (*E*)-(6-{2-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]vinyl}(4*R*,6*S*)-2,2-dimethyl[1,3]dioxan-4-yl)acetate having an X-ray powder diffraction pattern with peaks at 2-theta = 5.3, 7.1 and 18.9.


Claim 10 (previously presented): A crystalline compound of the formula (8) as defined in Claim 1, which crystalline compound is ethyl-(*E*)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3*R*,5*S*)-3,5-dihydroxyhept-6-enoate having an X-ray powder diffraction pattern with peaks at 2-theta = 8.1, 11.3 and 19.9.

Claim 11 (previously presented): A crystalline compound of the formula (8) as defined in Claim 1, which crystalline compound is iso-propyl-(*E*)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3*R*,5*S*)-3,5-dihydroxyhept-6-enoate having an X-ray powder diffraction pattern with peaks at 2-theta = 9.8, 17.3 and 21.1.

Claim 12 (cancelled).


Claim 13 (previously presented): A process for the manufacture of the calcium salt of (*E*)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3*R*,5*S*)-3,5-dihydroxyhept-6-enoic acid, comprising:

- a) acid hydrolysis of an acetal protecting group in a compound of formula (7)



7


wherein A is an acetal or ketal protecting group and R is (1-6C)alkyl, and isolation of the resulting crystalline compound of formula (10);



10

b) optional recrystallisation of the compound of the formula (10);

c) hydrolysis of the compound of formula (10) to give a dihydroxy carboxylate derivative of formula (9), wherein M is a metal counterion other than calcium,




9

or the calcium salt of (*E*)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3*R*,5*S*)-3,5-dihydroxyhept-6-enoic acid ; and

d) conversion of the compound of formula (9), where present, into the calcium salt of (*E*)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3*R*,5*S*)-3,5-dihydroxyhept-6-enoic acid.

Claim 14 (previously presented): A process as claimed in Claim 13 wherein the compound of formula (7) is a compound of formula (7a).



Claim 15 (original): A process for the manufacture of the calcium salt of (*E*)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3*R*,5*S*)-3,5-dihydroxyhept-6-enoic acid, from a crystalline compound of formula (10) as claimed in steps b) and c) of Claim 13.

Claim 16 (original): Crystalline (*E*)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3*R*,5*S*)-3,5-dihydroxyhept-6-enoic acid-(3,6)-lactone having an X-ray powder diffraction pattern with peaks at 2-theta = 7.9, 11.9, 15.9, 20.3, 21.7 and 22.5.

Claim 17 (original): A process for formation of amorphous bis[(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]](3R,5S)-3,5-dihydroxyhept-6-enoic acid] calcium salt comprising isolation of a crystalline compound as claimed in Claim 16 from a solution and subsequent conversion to the amorphous form of bis[(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]](3R,5S)-3,5-dihydroxyhept-6-enoic acid] calcium salt.

Claims 18-20 (cancelled).